Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marine Sivignon"'
Autor:
Aurélie Millier, Romain Supiot, Kelly Benyounes, Valérie Machuron, Katell Le Lay, Marine Sivignon, Claire Leboucher, Cécile Blein, François Raffi
Publikováno v:
Journal of Market Access & Health Policy, Vol 10, Iss 1 (2022)
Background Quantification of COVID-19 burden may be useful to support the future allocation of resources.Objective To evaluate the public health impact of COVID-19 in French ambulatory patients with at least one risk factor for severe disease.Study d
Externí odkaz:
https://doaj.org/article/127e431a65e14202bacc9742e0797ce4
Autor:
David Malka, Philippe Laramée, Mondher Toumi, Jean-Baptiste Trouiller, Bérengère Macabeo, Andrew Poll, Dan Howard, Andy Buckland, Marine Sivignon, Emilie Clay, Emmanuelle Samalin
Publikováno v:
BMJ Open, Vol 12, Iss 11 (2022)
Objective The BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibit
Externí odkaz:
https://doaj.org/article/223f47e391ee4605ad9203dec8cf7868
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0226196 (2020)
The aim of the study is to evaluate the cost-effectiveness of alectinib for first-line treatment of ALK+ advanced non-small-cell lung cancer compared to crizotinib in the French setting. This study used a partitioned survival model, with three discre
Externí odkaz:
https://doaj.org/article/965efe52adca4a0cbc227fb0a4257a35
Autor:
Jean-Baptiste Trouiller, Bérengère Macabeo, Andrew Poll, Dan Howard, Andy Buckland, Marine Sivignon, Emilie Clay, David Malka, Emmanuelle Samalin, Mondher Toumi, Philippe Laramée
Publikováno v:
BMJ open. 12(11)
ObjectiveThe BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::021233d3190c71f0af16647127fb5780
https://pubmed.ncbi.nlm.nih.gov/36410812
https://pubmed.ncbi.nlm.nih.gov/36410812
Autor:
Omar Dabbous, Lylia Chachoua, Samuel Aballéa, Marine Sivignon, Ulf Persson, Stavros Petrou, Jeff Richardson, Steven Simoens, Mondher Toumi
Publikováno v:
Advances in therapy.
We sought to synthesize published empirical studies that elicited and characterized societal valuations of orphan drugs and the attributes that may drive different valuations for orphan drugs versus other treatments.We conducted a systematic literatu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c80934f0b75d20f40ffe7d45ef5849c5
https://pubmed.ncbi.nlm.nih.gov/36451072
https://pubmed.ncbi.nlm.nih.gov/36451072
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 1, p e0226196 (2020)
PLoS ONE, Vol 15, Iss 1, p e0226196 (2020)
The aim of the study is to evaluate the cost-effectiveness of alectinib for first-line treatment of ALK+ advanced non-small-cell lung cancer compared to crizotinib in the French setting. This study used a partitioned survival model, with three discre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1dd95c7d483bff64b6b4ac3349da175
https://pubmed.ncbi.nlm.nih.gov/31945065
https://pubmed.ncbi.nlm.nih.gov/31945065